European Journal of Biomedical and Pharmaceutical Sciences

FORMULATION DEVELOPMENT AND CHARACTERIZATION OF RUTIN–DOCETAXEL CO-LOADED NANOPARTICLES AS A TARGETED DRUG DELIVERY SYSTEM FOR BREAST CANCER TREATMENT

Stuti Tiwari, Swarnali Das Paul, Rajesh Chaudhary, Jaya Shree*

ABSTRACT

The issue of breast cancer among women worldwide is a serious concern in health and the docetaxel is one of the most important drugs in chemotherapy and its weaknesses of not being soluble in water, excrete in a short period of time and slowdown in the tumor make the drug slow. In this piece of work, the development and trial of new nanoparticle drug delivery system that would include the combination of docetaxel- a drug that stabilizes the microtubules to avoid division of the cancer cells with rutin, a natural plant compound that is considered antioxidant in nature and slows down the development of cancer and has a potential of making the cancer cells be responsive to the treatment. The rutin-docetaxel nanoparticles have been prepared by a thin-film hydration approach thus the particles were even in size (120-180 nm), high drug loading (more than 85 percent entrapment), a negative charge in the surface, and slow release and it increased more rapidly in the acidic earlygins of the tumors. The combo showed extremely improve cell-killing activity in MCF-7 breast cancer cells- synergy scores less than 0.7, augmented cell killing through mediators, including caspase-3 activity, heightened levels of Bax proteins and decreased cancer cell migration was found in the laboratory. Overall, such an approach to nanoparticles improves the potential of docetaxel, its capacity to reach tumors and avoid the effect of resistant mechanisms, including p-glycoprotein pumps, which is a safer and more efficient way of breast cancer treatment with minimal side effects on normal tissues.

Keywords: Breast cancer, drug delivery system, nanoparticles, rutin, docetaxel, therapeutic efficacy, co-delivery, thin-film hydration, entrapment efficiency, pH responsive release, MCF-7 cells.